Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B. Domingo-Domenech J, et al. Among authors: campas c. Clin Cancer Res. 2006 Sep 15;12(18):5578-86. doi: 10.1158/1078-0432.CCR-05-2767. Clin Cancer Res. 2006. PMID: 17000695 Clinical Trial.
Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
Rojo F, González-Navarrete I, Bragado R, Dalmases A, Menéndez S, Cortes-Sempere M, Suárez C, Oliva C, Servitja S, Rodriguez-Fanjul V, Sánchez-Pérez I, Campas C, Corominas JM, Tusquets I, Bellosillo B, Serrano S, Perona R, Rovira A, Albanell J. Rojo F, et al. Among authors: campas c. Clin Cancer Res. 2009 May 15;15(10):3530-9. doi: 10.1158/1078-0432.CCR-08-2070. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417026
Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.
Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J. Rojo F, et al. Among authors: campas c. Clin Cancer Res. 2010 Apr 15;16(8):2474-82. doi: 10.1158/1078-0432.CCR-09-3042. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371675 Clinical Trial.
Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma.
Montraveta A, Xargay-Torrent S, López-Guerra M, Rosich L, Pérez-Galán P, Salaverria I, Beà S, Kalko SG, de Frias M, Campàs C, Roué G, Colomer D. Montraveta A, et al. Among authors: campas c. Oncotarget. 2014 Feb 15;5(3):726-39. doi: 10.18632/oncotarget.1455. Oncotarget. 2014. PMID: 24519895 Free PMC article.
Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
Campàs C, Cosialls AM, Barragán M, Iglesias-Serret D, Santidrián AF, Coll-Mulet L, de Frias M, Domingo A, Pons G, Gil J. Campàs C, et al. Exp Hematol. 2006 Dec;34(12):1663-9. doi: 10.1016/j.exphem.2006.07.008. Exp Hematol. 2006. PMID: 17157163 Free article.
Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.
Montraveta A, Xargay-Torrent S, Rosich L, López-Guerra M, Roldán J, Rodríguez V, Lee-Vergés E, de Frías M, Campàs C, Campo E, Roué G, Colomer D. Montraveta A, et al. Among authors: campas c. Oncotarget. 2015 Aug 28;6(25):21159-72. doi: 10.18632/oncotarget.4230. Oncotarget. 2015. PMID: 26110568 Free PMC article.
20 results